Foghorn Therapeutics Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
FHTX Nasdaq 8731 https://foghorntx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Foghorn Therapeutics Inc.

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer - Apr 16th, 2024 11:00 am
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs - Apr 9th, 2024 8:30 pm
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans - Apr 9th, 2024 10:34 am
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference - Apr 5th, 2024 11:00 am
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect? - Apr 2nd, 2024 1:55 pm
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting - Mar 26th, 2024 11:00 am
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know - Mar 13th, 2024 4:00 pm
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know - Mar 13th, 2024 1:55 pm
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates - Mar 7th, 2024 1:20 pm
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook - Mar 7th, 2024 12:00 pm
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909 - Mar 5th, 2024 9:48 pm
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? - Feb 28th, 2024 1:29 pm
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference - Feb 28th, 2024 12:00 pm
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last? - Feb 12th, 2024 7:43 am
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development - Feb 9th, 2024 3:02 pm
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor - Feb 8th, 2024 12:00 pm
With 39% stake, Foghorn Therapeutics Inc. (NASDAQ:FHTX) seems to have captured institutional investors' interest - Jan 11th, 2024 10:34 am
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024 - Jan 8th, 2024 12:00 pm
Foghorn Therapeutics Announces CFO Departure - Jan 3rd, 2024 9:05 pm
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why - Dec 26th, 2023 5:00 pm